Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Part I of the study (Dose Escalation): - To determine the Maximum Tolerated Dose (MTD) and the Dose Limiting Toxicities (DLT) of RO5126766 administered on an oral continuous daily schedule. Part II of the study (Expansion Cohort): - To investigate RO5126766 single agent activity in patients with metastatic or advanced solid tumor.
Critère d'inclusion
- To investigate RO5126766 single agent activity in patients with metastatic or advanced solid tumor